Review



prgn 3005 ultracar t muc16 ovarian cancer precigen  (Precigen Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Precigen Inc prgn 3005 ultracar t muc16 ovarian cancer precigen
    Prgn 3005 Ultracar T Muc16 Ovarian Cancer Precigen, supplied by Precigen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prgn+3005+ultracar+t+muc16+ovarian+cancer+precigen/pmc13126794-10-0-6
    Average 86 stars, based on 1 article reviews
    prgn 3005 ultracar t muc16 ovarian cancer precigen - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    Electroporation:

    Article Title: Are we there yet? The road to faster and more efficient CAR T cell manufacturing
    Article Snippet: GLPG5201 (CD19) CLL/RT CellPoint, Galapagos , Phase I/II 35–100 × 10 6 CAR + viable T cell , ORR: . at 35 × 10 6 cell dose: 83% . at 100 × 10 6 cell dose: 100% CRR: . at 35 × 10 6 cell dose: 67% . at 100 × 10 6 cell dose: 83% No CRS Grade ≥ 3 or ICANS , [ , ] . .. PRGN-3005 UltraCAR T (MUC16) Ovarian cancer Precigen , 1 day , 1 day (with or without lymphodepletion) , UltraPorator/ PoC , None , Electroporation (non-viral transposon: Sleeping Beauty) , NA , Phenotype: Express membrane-bound IL-15 (mbIL15) for enhanced in vivo expansion and kill switch genes Function: In vivo persistence for up to 9 months , No , Phase I/Ib ( NCT03907527 ) Without lymphodepletion: 0.1–65.5 × 10 5 /kg With lymphodepletion: 0.1–39 × 10 5 /kg , PRGN‐3005 was well tolerated up to at least 65.5 × 10 5 /kg with no dose‐limiting toxicities; 20% patients responded in at least one lesion , [ ] . .. PRGN-3006 UltraCAR T (CD33) AML MDS CMML Precigen , Phase I/Ib ( NCT03927261 ) Without lymphodepletion (C1): 1.8–50 × 10 5 CAR T cells With lymphodepletion (C2): 4.4–83 × 10 5 CAR T cells , PRGN-3006 infusion at up to 1 × 10 6 cells/kg was well tolerated ORR: 30% in AML patients. No response in CMML or MDS patients , [ ] .

    Membrane:

    Article Title: Are we there yet? The road to faster and more efficient CAR T cell manufacturing
    Article Snippet: GLPG5201 (CD19) CLL/RT CellPoint, Galapagos , Phase I/II 35–100 × 10 6 CAR + viable T cell , ORR: . at 35 × 10 6 cell dose: 83% . at 100 × 10 6 cell dose: 100% CRR: . at 35 × 10 6 cell dose: 67% . at 100 × 10 6 cell dose: 83% No CRS Grade ≥ 3 or ICANS , [ , ] . .. PRGN-3005 UltraCAR T (MUC16) Ovarian cancer Precigen , 1 day , 1 day (with or without lymphodepletion) , UltraPorator/ PoC , None , Electroporation (non-viral transposon: Sleeping Beauty) , NA , Phenotype: Express membrane-bound IL-15 (mbIL15) for enhanced in vivo expansion and kill switch genes Function: In vivo persistence for up to 9 months , No , Phase I/Ib ( NCT03907527 ) Without lymphodepletion: 0.1–65.5 × 10 5 /kg With lymphodepletion: 0.1–39 × 10 5 /kg , PRGN‐3005 was well tolerated up to at least 65.5 × 10 5 /kg with no dose‐limiting toxicities; 20% patients responded in at least one lesion , [ ] . .. PRGN-3006 UltraCAR T (CD33) AML MDS CMML Precigen , Phase I/Ib ( NCT03927261 ) Without lymphodepletion (C1): 1.8–50 × 10 5 CAR T cells With lymphodepletion (C2): 4.4–83 × 10 5 CAR T cells , PRGN-3006 infusion at up to 1 × 10 6 cells/kg was well tolerated ORR: 30% in AML patients. No response in CMML or MDS patients , [ ] .

    In Vivo:

    Article Title: Are we there yet? The road to faster and more efficient CAR T cell manufacturing
    Article Snippet: GLPG5201 (CD19) CLL/RT CellPoint, Galapagos , Phase I/II 35–100 × 10 6 CAR + viable T cell , ORR: . at 35 × 10 6 cell dose: 83% . at 100 × 10 6 cell dose: 100% CRR: . at 35 × 10 6 cell dose: 67% . at 100 × 10 6 cell dose: 83% No CRS Grade ≥ 3 or ICANS , [ , ] . .. PRGN-3005 UltraCAR T (MUC16) Ovarian cancer Precigen , 1 day , 1 day (with or without lymphodepletion) , UltraPorator/ PoC , None , Electroporation (non-viral transposon: Sleeping Beauty) , NA , Phenotype: Express membrane-bound IL-15 (mbIL15) for enhanced in vivo expansion and kill switch genes Function: In vivo persistence for up to 9 months , No , Phase I/Ib ( NCT03907527 ) Without lymphodepletion: 0.1–65.5 × 10 5 /kg With lymphodepletion: 0.1–39 × 10 5 /kg , PRGN‐3005 was well tolerated up to at least 65.5 × 10 5 /kg with no dose‐limiting toxicities; 20% patients responded in at least one lesion , [ ] . .. PRGN-3006 UltraCAR T (CD33) AML MDS CMML Precigen , Phase I/Ib ( NCT03927261 ) Without lymphodepletion (C1): 1.8–50 × 10 5 CAR T cells With lymphodepletion (C2): 4.4–83 × 10 5 CAR T cells , PRGN-3006 infusion at up to 1 × 10 6 cells/kg was well tolerated ORR: 30% in AML patients. No response in CMML or MDS patients , [ ] .



    Similar Products

    prgn 3005 ultracar t muc16 ovarian cancer precigen  (Precigen Inc)
    86
    Precigen Inc prgn 3005 ultracar t muc16 ovarian cancer precigen
    Prgn 3005 Ultracar T Muc16 Ovarian Cancer Precigen, supplied by Precigen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prgn+3005+ultracar+t+muc16+ovarian+cancer+precigen/pmc13126794-10-0-6
    Average 86 stars, based on 1 article reviews
    prgn 3005 ultracar t muc16 ovarian cancer precigen - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results